Brainsway Ltd (BWAY)vsStryker Corporation (SYK)
BWAY
Brainsway Ltd
$9.39
-7.12%
HEALTHCARE · Cap: $406.96M
SYK
Stryker Corporation
$309.64
+0.35%
HEALTHCARE · Cap: $118.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 43231% more annual revenue ($26.30B vs $60.70M). BWAY leads profitability with a 15.6% profit margin vs 13.8%. SYK trades at a lower P/E of 33.3x. SYK earns a higher WallStSmart Score of 53/100 (C-).
BWAY
Buy51
out of 100
Grade: C-
SYK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BWAY.
Margin of Safety
-31.3%
Fair Value
$235.85
Current Price
$309.64
$73.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.4% year-over-year
Earnings expanding 59.8% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Strong operational efficiency at 24.0%
Generating 1.2B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BWAY profiles as a growth stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.77 — expect wider price swings.
BWAY is growing revenue faster at 35.4% — sustainability is the question.
SYK generates stronger free cash flow (1.2B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (53/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?